AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02591420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg of VRC01 will be administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
Study NCT02591420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for VRC01
Description: Administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
Study NCT02591420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) (regimen will vary within countries and by patient)
Description: ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
Study NCT00197028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02D
Description: 3-dose intramuscular injection in the thigh
Study NCT00197028 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRActHib™
Description: 3-dose intramuscular injection in the thigh.
Study NCT00197028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRActHib™
Description: 3-dose intramuscular injection in the thigh.
Study NCT00197028 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B®
Description: 3-dose intramuscular injection in the thigh.
Study NCT00247624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone 3 mg every night for 8 weeks
Study NCT00247624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine 20 mg every morning for 9 weeks
Study NCT00247624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine 20 mg every morning for 9 weeks
Study NCT00247624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo every night for 8 weeks
Study NCT01915199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Care
Description: Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
Study NCT01702389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study NCT02412384 — intervention group
Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.
Study NCT02412384 — intervention group
Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study NCT02830165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02830165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02830165 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT01440725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-rich plasma (PRP)
Description: 4-8cc, a single dose
Study NCT01440725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evacuation of haematoma
Description: Evacuation of the haematoma, a single procedure
Study NCT06181851 — intervention group
Intervention type: OTHER
Intervention: Analysis of microbiome and metabolomics
Description: Analysis of microbiome and metabolomics through the assessment of blood and semen parameters
Study NCT04464447 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy
Description: The treatment ACT for Health in Adolescents (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module. Six to eight patients participate in each treatment Group. An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module.
Study NCT01363843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: FOLFOX6
Study NCT01363843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT with concurrent chemotherapy
Description: IMRT 50.4Gy with chemotherapy
Study NCT01363843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT00820105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: oral administration
Study NCT00820105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: Oral administration
Study NCT00820105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADX10059 Matching Placebo
Description: Oral administration
Study NCT03885284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~* Irinotecan 150 mg/m2 IV day 1~* Oxaliplatin 85 mg/m2 IV day 1~* Leucovorin 400 mg/m2 IV day 1~* 5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~* Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~* Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3.
Study NCT03885284 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam radiation
Description: Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7
Study NCT02948166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty with stenting of the femoral artery
Description: A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
Study NCT02948166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open surgery
Description: Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
Study NCT05312502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth Ball
Description: During labour, the pregnant woman was positioned using a birth ball.
Study NCT02522637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each \< 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%.
Study NCT02522637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each \< 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%.
Study NCT03542214 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Patients with inoperable colorectal cancer will be treated with calcium electroporation
Study NCT00837460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: 4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
Study NCT01371682 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropinirole XL
Description: Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
Study NCT01642160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: additional educational material
Description: The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
Study NCT01642160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: participants will receive education from staff nurses as needed.
Study NCT03423693 — intervention group
Intervention type: OTHER
Intervention: No any intervention
Description: No any intervention is applied to any groups in this study
Study NCT01529268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DR cysteamine bitartrate capsule
Description: * 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline
Study NCT01529268 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DR cysteamine bitartrate placebo
Description: * 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline
Study NCT01522053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter-over-needle
Description: Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
Study NCT01522053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter-through-needle
Description: Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
Study NCT03181555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exploratory
Study NCT00232882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan Thiazide
Description: Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
Study NCT00232882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol Thiazide
Description: Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
Study NCT00232882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide Candesartan
Description: Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
Study NCT01937338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7624
Description: nebuliser solution; 20 mg/mL for inhalation
Study NCT01937338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nebuliser solution for inhalation
Study NCT01258868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: 400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.
Study NCT01258868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor cell vaccine
Description: A minimum of 1x10e7 and a maximum of 1x10e8 patient tumor cells that have been exposed to 1 mcM decitabine for 6 days, exposed to 100 Gy radiation and emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections; if subject shows immune response, vaccine will be given every three months from months 9 - 24
Study NCT02656368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEBORRHEAMEDIS Face Cream
Description: SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
Study NCT04003272 — intervention group
Intervention type: DEVICE
Intervention: Comprehensive Reverse Versa-Dial Titanium Glenosphere
Description: Implant used for patients with allergy to typical device material metals to repair shoulder malfunction/disease.
Study NCT03597711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVcannulation
Description: Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants
Study NCT02736214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reproductive Life Plan (RLP)
Description: A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
Study NCT02229604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EA
Description: For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.
Study NCT02229604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRT, DHEA and herb
Description: HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
Study NCT02229604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRT, DHEA and herb
Description: HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
Study NCT01023477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Standard Dose (500mg/week)
Description: Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
Study NCT01023477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Low Dose (250mg/week)
Description: Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
Study NCT01023477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Biopsy
Description: Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.
Study NCT00582816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinimacs Cell Separation System
Description: Depletion of T-cells
Study NCT00582816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conditioning chemotherapy
Description: Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
Study NCT00582816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DLI
Description: NK Cell selected DLI
Study NCT02129777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namilumab
Description: Namilumab subcutaneous injection
Study NCT02129777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT03232125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
Study NCT03232125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
Study NCT03485495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divaza
Description: Oral administration.
Study NCT03485495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study NCT01677312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic Biopsy
Description: A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
Study NCT01677312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Histological Samples
Description: The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
Study NCT01944839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030
Study NCT01944839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT01944839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Study NCT01944839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E10030 sham intravitreal injection
Description: Pressure on the eye with a syringe with no needle
Study NCT03332511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 300mg twice-daily
Study NCT03222492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
Study NCT02242240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol twice daily
Study NCT01645761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endonase
Description: PPI- based triple therapy with endonase
Study NCT04232449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREDNISON Galepharm Tabl. 20 mg
Description: 5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone
Study NCT04232449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: 5 daily- doses of placebo (2 tablets)
Study NCT05191628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Visio-AMTRIX
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane placed by the investigator during macular hole surgery
Study NCT02848547 — intervention group
Intervention type: BEHAVIORAL
Intervention: Text Messaging via Short Message Service
Study NCT03251547 — intervention group
Intervention type: DRUG
Intervention: NovoSeven
Description: To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
Study NCT02986373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous injection.
Study NCT01615510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol immediate release
Description: 100 mg, single administration
Study NCT01615510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, single administration
Study NCT02603575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: 70mg ivdrip the first day, then 50mg ivdrip qd